Callio Therapeutics
PrivateLast Round
Series A
Mar 3, 2025
Total Funding Raised
$187M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Callio Therapeutics is a biotechnology company that develops next-generation, multi-payload antibody-drug conjugates (ADCs) for cancer therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Callio Therapeutics Comparables
Compare Callio Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Canwell Biotech Ltd. | 86% | |
| Eli Lilly and Company | 83% | |
| NetTargets | 78% |
Callio Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 3, 2025 |
Key People
Founding team and executive leadership
Callio Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series A |
| SEEDS Capital | Series A |
| ClavystBio | Series A |
| EDBI | Series A |
| Norwest Venture Partners | Series A |
| Frazier Life Sciences | Series A |
| Novo Holdings | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 25, 2026
Grew 16% QoQ, from 19 to 22 employees.
- Jul 23, 2026
Grew 18% QoQ, from 17 to 20 employees.
Recent news
Latest coverage and updates
- hiresSep 10, 2026
Callio Therapeutics, Inc. hired Zachary Hornby as Chief Executive Officer on Sep 9th '26.
- is_developingSep 9, 2026
Callio Therapeutics, Inc. is developing dual-payload antibody-drug conjugates on Jul 1st '25.
Callio Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Callio Therapeutics's valuation, stock price, and market status.
Is Callio Therapeutics a public or private company?
Callio Therapeutics is a private company.
What is the current stock price of Callio Therapeutics?
Callio Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Callio Therapeutics worth (valuation)?
Valuation information for Callio Therapeutics is not publicly available.
Can I buy Callio Therapeutics stock?
Callio Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Callio Therapeutics's last funding round?
Callio Therapeutics's most recent funding round was Series A on March 3, 2025.
Who are the main investors in Callio Therapeutics?
Key investors in Callio Therapeutics include Frazier Life Sciences.
Will Callio Therapeutics IPO soon?
No public IPO plans have been announced for Callio Therapeutics.
How can I track Callio Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Callio Therapeutics's secondary market activity and sign up for updates.